M

    MAIA Biotechnology Inc. (MAIA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.30
    -0.03 (-2.26%)

    Market Cap: $80.91M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(11/16)
    Avg Surprise
    +6.93%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.12
    Range$-0.12 - $-0.12
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.16-33.3%
    60d ago$-0.16-33.3%
    30d ago$-0.12+0.0%
    7d ago$-0.12+0.0%
    Current$-0.12
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.13 - $-0.13
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$-0.12---
    Jun 26
    		$-0.13$-0.11-18.18%Miss+27.8%
    Mar 26
    		$-0.14$-0.18+22.22%Beat+12.5%
    Dec 25
    		$-0.14$-0.13-5.23%Miss+57.3%
    Sep 25
    		$-0.27$-0.19-42.11%Miss-145.5%
    Jun 25
    		$-0.18$-0.25+28.00%Beat+55.0%
    Mar 25
    		$-0.16$-0.18+11.11%Beat+65.2%
    Dec 24
    		$-0.32$-0.35+8.57%Beat+20.0%
    Sep 24
    		$-0.11N/A+76.60%Beat+69.4%
    Jun 24
    		$-0.40$-0.41+2.44%Beat-14.3%
    Mar 24
    		$-0.46$-0.39-17.95%Miss-21.1%
    Dec 23
    		$-0.40$-0.39-2.56%Miss-14.3%
    Sep 23
    		$-0.36$-0.38+5.26%Beat+26.5%
    Jun 23
    		$-0.35$-0.43+18.60%Beat-400.0%
    Mar 23
    		$-0.38$-0.42+9.52%Beat+62.7%
    Dec 22
    		$-0.35$-0.41+14.63%Beat-
    Sep 22
    		$-0.49$-0.49+0.00%Beat-
    Jun 22
    		$-0.07$0.00N/AMiss-
    Sep 21
    		$-1.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.92EV/EBITDA-2.34x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-218.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.51xQuick Ratio4.51x
    Trading Statistics
    Beta0.25Avg Volume354.91K
    52-Week High$3.1952-Week Low$0.87

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.37
    SMA 20$1.38
    SMA 50$1.37
    SMA 200$1.47
    EMA 10$1.36
    EMA 20$1.36
    EMA 50$1.36
    EMA 200$1.46

    MACD

    Line: -0.00Signal: 0.01Hist: -0.01

    ADX

    ADX: 14.7+DI: 17.5-DI: 21.2

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down12.0
    PSAR$1.47

    Bollinger Bands

    Upper Band$1.44
    Lower Band$1.32
    %B Position895%(Upper)
    Band Width-0.14

    RSI (14-Day)

    Neutral
    41.9

    Momentum Oscillators

    Stoch %K15.7
    Stoch %D30.8
    Williams %R-97.2
    ROC (10d)-6.5%
    Momentum-0.09
    CCI (20d)-238.7
    MFI (14d)56.6

    Volatility Measures

    ATR (14d)$0.06(4.8%)
    StdDev (20d)0.03
    Hist Vol37.8%(Moderate)

    Volume Flow

    VWAP$1.31
    OBV52.9M
    AD Line-17.0M
    CMF (20d)-0.004

    Volume Metrics

    Avg Vol (20d)340.1K
    Vol Ratio0.8x
    VWMA (20d)$1.38

    Pivot Points

    R3$1.43
    R2$1.40
    R1$1.37
    Pivot Point$1.34
    S1$1.31
    S2$1.28
    S3$1.25

    Advanced Oscillators

    TSI-0.22
    Ultimate Osc39.3
    KST16.08

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0N/A$0
    Operating Expenses$8.32M$6.95M$4.32M$9.36M$5.17M$5.43M$5.02M$4.19M$3.80M$3.95M$6.49M$4.90M
    R&D$5.64M$3.53M$1.88M$6.36M$3.11M$3.20M$2.99M$2.67M$2.03M$2.32M$3.83M$2.54M
    SG&A$2.68M$3.42M$2.44M$3.00M$2.06M$2.23M$2.04M$1.52M$1.76M$1.63M$2.66M$2.36M
    Operating Income$-8,317,251$-6,949,929$-4,317,271$-9,360,926$-5,166,058$-5,425,431$-5,004,604$-4,188,468$-3,815,262$-3,948,876$-6,377,842$-4,955,643
    Interest Income$207,173$213,565$0$0$0$0$0$0$88,383$44,118$30,722$3,260
    Interest Expense$0$0$0$0$180,905$0$0$0$5.08M$4.12M$0$1
    Income Before Tax$-7,943,587$-6,369,652$-3,628,761$-8,903,189$-5,346,963$-4,517,259$-3,553,890$-2,735,987$-8,897,324$-8,067,455$-6,216,896$-4,875,743
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-7,943,587$-6,369,652$-3,628,761$-8,903,189$-5,346,963$-4,517,259$-3,571,938$-2,735,987$-8,879,276$-8,067,455$-6,256,662$-4,875,743
    EBITDA$-8,150,760$-6,583,217$-3,828,231$-8,903,189$-5,346,963$-4,517,259$-3,408,465$-2,735,902$-8,985,707$-8,111,573$-6,137,927$-4,937,450
    EBIT$-8,150,760$-6,583,217$-3,828,231$-8,903,189$-5,346,963$-4,517,259$-3,408,465$-2,735,902$-8,985,707$-8,111,573$-6,137,927$-4,937,450
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MAIA

    News

    Centric Wealth Management Takes Position in MAIA Biotechnology, Inc. $MAIA

    Centric Wealth Management has acquired a new position in MAIA Biotechnology, purchasing 796,723 shares valued at approximately $1.11 million, representing a 1.31% stake. Other institutional investors and company insiders, including CEO Vlad Vitoc and Director Stan Smith, have also increased their holdings, bringing total institutional ownership to 5.65%. MAIA Biotechnology, a clinical-stage biopharmaceutical company, focuses on developing antibody-based diagnostic and targeted radiotherapeutic treatments for cancer.

    MarketBeat•8/16/26•
    Bullish

    Solas Capital discloses 4.9% MAIA Biotechnology (MAIA) stake in Schedule 13G/A

    Solas Capital Management, LLC and Frederick Tucker Golden have reported a 4.9% beneficial ownership stake in MAIA Biotechnology, Inc. This stake, totaling 3,030,845 shares of common stock, is held through two private funds for the benefit of their investors. Both Solas Capital and Golden exercise shared voting and dispositive power over these shares, as detailed in their Schedule 13G/A filing.

    Stock Titan•8/14/26•
    Neutral

    MAIA Biotechnology Q2 Results: EPS misses estimates

    MAIA Biotechnology reported a Q2 loss of $(0.13) per share, missing the analyst consensus of $(0.11) by 18.18%. Despite the quarterly miss, the company showed a significant year-over-year improvement, reducing losses by 27.78% compared to $(0.18) in the same period last year. This indicates progress in reducing its per-share deficit, even as short-term targets were not met.

    scanx.trade•8/10/26•
    Neutral

    MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q Summary

    MAIA Biotechnology, Inc. reported a net loss of $(14.31M) for the first six months of 2026, an increase from the $(9.86M) loss in the same period of 2025, while remaining pre-revenue. Diluted loss per share narrowed to $(0.27) from $(0.34) year-over-year. The company highlighted significant clinical progress, regulatory clearances, a $33M equity offering, and plans for pipeline expansion.

    TradingView•8/10/26•
    Neutral

    Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates

    Maia Biotechnology Inc (MAIA) has a target price forecast of $14.00, with one analyst recommending a "Buy" rating. The company's recent EPS was -$0.10, outperforming market expectations of -$0.14, and the next quarter's EPS is projected to be -$0.11. Despite these forecasts, the article notes that specific future EPS, revenue, net profit, and EBIT data have not yet been disclosed by the company.

    TradingKey•8/7/26•
    Somewhat-Bullish

    Frequently Asked Questions About MAIA

    Does MAIA pay dividends?
    MAIA Biotechnology Inc. (MAIA) does not currently pay a regular dividend.
    What is MAIA's market cap?
    MAIA Biotechnology Inc. (MAIA) has a market capitalization of $80.91M with a current stock price of $1.30.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In